◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Kopran Limited (KOPRAN) Financial History

Name: Kopran Limited (KOPRAN) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - General · DATA UPDATED 2026-09-20

Kopran Limited (KOPRAN) operates in the Drug Manufacturers - General industry and is headquartered in Mumbai, India with about 1,156 employees. Its market capitalization is roughly ₹13 billion. In the fiscal year ended 2026-03-31, KOPRAN reported ₹6.8B in revenue and ₹257M in net income.

Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally.

Interactive charts & full statements →

KOPRAN Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹6.8B	₹6.2B	₹6.1B	₹5.5B	—
Gross Profit	₹2.2B	₹2.1B	₹1.9B	₹1.7B	—
Operating Income (EBIT)	₹611M	₹573M	₹615M	₹453M	—
Net Income	₹257M	₹386M	₹510M	₹272M	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KOPRAN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹1.5B	₹2.3B	₹1.9B	₹1.2B	₹1.4B
Gross Profit	₹628M	₹875M	₹632M	₹419M	₹498M
Operating Income (EBIT)	₹100M	₹361M	₹158M	(₹13M)	₹99M
Net Income	₹67M	₹189M	₹93M	(₹99M)	₹74M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KOPRAN Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹145M)	(₹145M)	(₹145M)	(₹145M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KOPRAN Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹9.1B	₹8.4B	₹7.4B	₹6.5B	—
Total Liabilities	₹3.8B	₹3.3B	₹2.5B	₹2.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KOPRAN viewer.

Other Companies in Drug Manufacturers - General

SAIPARENT · Sai Parenteral's Limited — ₹23 billion
NGLFINE · NGL Fine-Chem Limited — ₹17 billion
TTKHLTCARE · TTK Healthcare Limited — ₹15 billion
2630 · Vigonvita Life Sciences Co., Ltd. — HK$14 billion
9637 · Alebund Pharmaceuticals (Jiangsu) Limited — HK$8 billion
1666 · Tong Ren Tang Technologies Co. Ltd. — HK$4 billion
VIRP · Virbac SA — €3 billion
1643 · Modern Chinese Medicine Group Co., Ltd. — HK$562 million

← KOPN All “K” companies KORP →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.